David A. Happel
2016
In 2016, David A. Happel earned a total compensation of $1.6M as Executive Vice President, Orphan Business Unit at Horizon Pharma.
Compensation breakdown
| Bonus | $129,000 |
|---|---|
| Non-Equity Incentive Plan | $156,975 |
| Option Awards | $582,818 |
| Salary | $103,288 |
| Stock Awards | $582,496 |
| Other | $16,847 |
| Total | $1,571,424 |
Happel received $582.8K in option awards, accounting for 37% of the total pay in 2016.
Happel also received $129K in bonus, $157K in non-equity incentive plan, $103.3K in salary, $582.5K in stock awards and $16.8K in other compensation.
Rankings
In 2016, David A. Happel's compensation ranked 6,033rd out of 14,075 executives tracked by ExecPay. In other words, Happel earned more than 57.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,033 out of 14,075 | 57th |
Division Manufacturing | 2,197 out of 5,488 | 60th |
Major group Chemicals And Allied Products | 718 out of 1,900 | 62nd |
Industry group Drugs | 540 out of 1,543 | 65th |
Industry Pharmaceutical Preparations | 423 out of 1,173 | 64th |
Source: SEC filing on April 3, 2017.
Happel's colleagues
We found four more compensation records of executives who worked with David A. Happel at Horizon Pharma in 2016.